Ignacio Garrido-Laguna

Summary

Publications

  1. doi request reprint Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:1422-8. 2012
  2. doi request reprint The inverted pyramid of biomarker-driven trials
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 8:562-6. 2011
  3. pmc PIK3CA mutations in advanced cancers: characteristics and outcomes
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 3:1566-75. 2012
  4. pmc KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e38033. 2012
  5. pmc PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e22769. 2011
  6. doi request reprint Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience
    David S Hong
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Colorectal Cancer 11:297-303. 2012
  7. pmc Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 16:327-35. 2011
  8. ncbi request reprint Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors
    David S Hong
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 120:2164-73. 2014
  9. pmc PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
    Filip Janku
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:777-82. 2012
  10. ncbi request reprint Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, University of Texas M D Anderson Cancer Center, 1515Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 16:4031-7. 2010

Detail Information

Publications12

  1. doi request reprint Validation of the Royal Marsden Hospital prognostic score in patients treated in the Phase I Clinical Trials Program at the MD Anderson Cancer Center
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    Cancer 118:1422-8. 2012
    ....
  2. doi request reprint The inverted pyramid of biomarker-driven trials
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA
    Nat Rev Clin Oncol 8:562-6. 2011
    ..We expect that these new strategies will enhance response rates as appropriate patients are targeted, therefore sparing those patients who are unlikely to benefit...
  3. pmc PIK3CA mutations in advanced cancers: characteristics and outcomes
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Oncotarget 3:1566-75. 2012
    ..PIK3CA mutations, especially, H1047R, were associated with attaining a PR/CR to PI3K/AKT/mTOR pathway inhibitors...
  4. pmc KRASness and PIK3CAness in patients with advanced colorectal cancer: outcome after treatment with early-phase trials with targeted pathway inhibitors
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 7:e38033. 2012
    ..To evaluate clinicopathologic and molecular features of patients with metastatic colorectal cancer (mCRC) and their outcomes in early-phase trials using pathway-targeting agents...
  5. pmc PIK3CA mutations frequently coexist with RAS and BRAF mutations in patients with advanced cancers
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, United States of America
    PLoS ONE 6:e22769. 2011
    ..Oncogenic mutations of PIK3CA, RAS (KRAS, NRAS), and BRAF have been identified in various malignancies, and activate the PI3K/AKT/mTOR and RAS/RAF/MEK pathways, respectively. Both pathways are critical drivers of tumorigenesis...
  6. doi request reprint Outcomes in 144 patients with colorectal cancer treated in a phase I clinic: the MD Anderson Cancer Center experience
    David S Hong
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA
    Clin Colorectal Cancer 11:297-303. 2012
    ..Patients with advanced colorectal cancer have a poor prognosis once standard therapies fail. This retrospective study presents the characteristics and outcomes in 144 patients treated in phase I clinical trials...
  7. pmc Outcomes of patients with advanced non-small cell lung cancer treated in a phase I clinic
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Oncologist 16:327-35. 2011
    ..The outcomes of patients with advanced non-small cell lung cancer (NSCLC) treated in phase I clinical trials have not been systematically analyzed...
  8. ncbi request reprint Dual inhibition of the vascular endothelial growth factor pathway: A phase 1 trial evaluating bevacizumab and AZD2171 (cediranib) in patients with advanced solid tumors
    David S Hong
    Department of Investigational Cancer Therapeutics Phase I Program, The University of Texas MD Anderson Cancer Center, Houston, Texas
    Cancer 120:2164-73. 2014
    ..The current study was conducted to evaluate the safety and biological activity of dual inhibition of the vascular endothelial growth factor (VEGF) pathway with combined bevacizumab and cediranib (a VEGF receptor tyrosine kinase inhibitor)...
  9. pmc PI3K/AKT/mTOR inhibitors in patients with breast and gynecologic malignancies harboring PIK3CA mutations
    Filip Janku
    The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    J Clin Oncol 30:777-82. 2012
    ..Concomitant mutations in the mitogen-activated protein kinase (MAPK) pathway may mediate resistance...
  10. ncbi request reprint Patients with advanced head and neck cancers have similar progression-free survival on phase I trials and their last food and drug administration-approved treatment
    Ignacio Garrido-Laguna
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, University of Texas M D Anderson Cancer Center, 1515Holcombe Boulevard, Houston, TX 77030, USA
    Clin Cancer Res 16:4031-7. 2010
    ....
  11. pmc PIK3CA mutations in patients with advanced cancers treated with PI3K/AKT/mTOR axis inhibitors
    Filip Janku
    Department of Investigational Cancer Therapeutics, The University of Texas M D Anderson Cancer Center, 1515 Holcombe Blvd, FC8 2057, Box 0455, Houston, TX 77030, USA
    Mol Cancer Ther 10:558-65. 2011
    ..5% of patients with diverse solid tumors. The response rate was significantly higher for patients with PIK3CA mutations treated with PI3K/AKT/mTOR pathway inhibitors than for those without documented mutations...
  12. ncbi request reprint Novel therapeutic targets in non-small cell lung cancer
    Filip Janku
    Department of Investigational Cancer Therapeutics Phase I Clinical Trials Program, The University of Texas MD Anderson Cancer Center, Houston, Texas 77030, USA
    J Thorac Oncol 6:1601-12. 2011
    ..This review describes molecular targets in non-small cell lung cancer that are in development or being clinically applied and their implications for developing novel anticancer therapies for this previously refractory malignancy...